KYORIN Pharmaceutical Co.,Ltd. [4569.T]
TOKYO, May 12 (Pulse News Wire) – Kyorin Pharmaceutical CO.,LTD. (4569.T) reported its fiscal year 2026 (April 1, 2025 to March 31, 2026) earnings results, which fell short of previously announced forecasts.
For the fiscal year ending March 31, 2026, revenue was forecast at ¥127.0 billion but came in at ¥126.3 billion, a decrease of --¥743 million or -0.6%. Operating profit was projected at ¥6.100 billion but dropped to ¥3.567 billion, marking a decline of 41.5%. Ordinary profit also saw a significant drop from ¥6.300 billion to ¥4.031 billion, representing a reduction of 36%. On a per-share basis, net income attributable to shareholders of the parent company decreased from ¥83.5 million to ¥60.0 million, a difference of --¥23.5 million or -28.2%. In addition, individual performance figures showed similar discrepancies.
Revenue was expected at ¥111.1 billion but reached only ¥110.9 billion, a slight deviation of -0.1%. Operating profit declined from ¥6.300 billion to ¥4.285 billion, a drop of 32%, while ordinary profit went down from ¥6.800 billion to ¥5.048 billion, reflecting a 25.8% decrease. The shortfall in sales was attributed to lower-than-expected revenues from certain key products. Additionally, research and development expenses increased due to upfront payments for newly introduced products, contributing to reduced operating and ordinary profits. This marks a significant divergence from previous expectations and highlights challenges faced by the pharmaceutical firm during the fiscal year.
🟢 Confidence: High AI-translated content.